Recombinant Human Uncharacterized protein C18orf1 (C18orf1)

What is the basic structure of human C18orf1 protein?

C18orf1 is a human protein encoded by the C18orf1 gene located on chromosome 18. The full-length protein consists of 306 amino acids with a transmembrane domain structure. Its amino acid sequence is: MPEAGFQATNAFTECKFTCTSGKCLYLGSLVCNQQNDCGDNSDEENCLLVTEHPPPGIFNSELEFAQIIIIVVVVTVMVVVIVCLLNHYKVSTRSFINRPNQSRRREDGLPQEGCLWPSDSAAPRLGASEIMHAPRSRDRFTAPSFIQRDRFSRFQPTYPYVQHEIDLPPTISLSDGEEPPPYQGPCTLQLRDPEQQMELNRESVRAPPNRTIFDSDLIDIAMYSGGPCPPSSNSGISASTCSSNGRMEGPPPTYSEVMGHHPGASFLHHQRSNAHRGSRLQFQQNNAESTIVPIKGKDRKPGNLV . Structurally, C18orf1 possesses two PY motifs and one Smad-interacting motif (SIM) domain, sharing structural similarities with TMEPAI (transmembrane prostate androgen-induced RNA) .

What is the known functional role of C18orf1 in cellular signaling?

C18orf1 functions primarily as a negative regulator of Transforming Growth Factor-β (TGF-β) signaling. Research demonstrates that C18orf1 inhibits TGF-β signaling specifically, without affecting Bone Morphogenetic Protein (BMP) signaling pathways . The protein acts as a cellular "gatekeeper" that abrogates excessive TGF-β signaling by competing with Smad Anchor for Receptor Activation (SARA) for Smad2/3 binding. This competition attenuates the recruitment of Smad2/3 to the TGF-β type I receptor (also known as activin receptor-like kinase 5 or ALK5) . Unlike its family member TMEPAI, C18orf1 is not induced by TGF-β signaling, suggesting it functions as a constitutive surveillant during the steady state of TGF-β signaling .

How does C18orf1 differ from other similar regulatory proteins?

While C18orf1 shares structural features with TMEPAI, including two PY motifs and one SIM domain, there are important functional differences. Both proteins can block TGF-β signaling through similar mechanisms, but C18orf1 is not induced upon TGF-β signaling, whereas TMEPAI is . This distinction suggests different roles in the regulation of TGF-β pathway: C18orf1 appears to function as a constitutive surveillance mechanism during steady-state conditions, while TMEPAI might help C18orf1 inhibit TGF-β signaling in a coordinated manner when cells are exposed to high levels of TGF-β . This complementary relationship allows for nuanced regulation of TGF-β signaling under different cellular conditions.

What are the optimal storage and handling conditions for recombinant C18orf1 protein?

Recombinant C18orf1 protein should be stored at -20°C for routine use, or at -80°C for extended storage periods. The protein is typically supplied in a Tris-based buffer with 50% glycerol optimized for stability . To maintain protein integrity, avoid repeated freeze-thaw cycles, as these can lead to protein denaturation and loss of activity. Instead, prepare small working aliquots and store them at 4°C for up to one week during active experimentation . When handling the protein, maintain sterile conditions and use appropriate personal protective equipment to prevent contamination and degradation.

What methodologies are most effective for studying C18orf1 interactions with Smad proteins?

To study C18orf1 interactions with Smad proteins, researchers typically employ several complementary approaches:

• Co-immunoprecipitation (Co-IP): This technique can effectively demonstrate physical interactions between C18orf1 and Smad proteins, particularly Smad2/3. Studies have shown that AR-Smads can bind to C18orf1α1, while BMP-specific R-Smads (BR-Smads), Smad4, and Smad7 do not interact with C18orf1α1 .

• Mutation analysis: Creating mutations in the SIM domain of C18orf1 and assessing the impact on Smad binding capabilities. Research has shown that mutations in the SIM domain cause C18orf1α1 to lose its ability to bind to Smad proteins .

• Phosphorylation assays: These can be used to assess how C18orf1 affects ALK5-mediated Smad3 phosphorylation or ALK4-mediated Smad2 phosphorylation. C18orf1α1 has been shown to counteract both of these phosphorylation events .

• Competition assays: These experiments can demonstrate how C18orf1 competes with SARA for Smad2/3 binding, providing insight into the mechanism by which C18orf1 regulates TGF-β signaling .

How can researchers effectively measure the inhibitory effects of C18orf1 on TGF-β signaling?

To quantify C18orf1's inhibitory effects on TGF-β signaling, researchers should consider multiple approaches:

• Reporter gene assays: Utilize TGF-β-responsive luciferase reporter constructs to measure pathway activity in the presence and absence of C18orf1. This approach provides a quantitative readout of transcriptional responses.

• Western blotting for phospho-Smads: Track the phosphorylation status of Smad2 and Smad3 following TGF-β stimulation, with and without C18orf1 expression. Research has shown that C18orf1α1 suppresses phosphorylation of AR-Smads upon both TGF-β and activin stimulation in cells .

• RT-qPCR for TGF-β target genes: Measure expression levels of known TGF-β-regulated genes such as JunB, p21, and TMEPAI. Knockdown of C18orf1 has been shown to potentiate the expression of these mRNAs induced by TGF-β .

• Cell migration assays: As TGF-β-induced cell migration is enhanced by the knockdown of C18orf1, migration assays can serve as a functional readout of C18orf1's inhibitory effects .

• Smad nuclear translocation: Monitor Smad2/3 nuclear accumulation following TGF-β exposure using immunofluorescence or subcellular fractionation in the presence or absence of C18orf1.

How does C18orf1 participate in the regulation of Epithelial-Mesenchymal Transition (EMT)?

C18orf1's role in EMT regulation stems from its inhibitory effect on TGF-β signaling, a major inducer of EMT. Experiments involving knockdown of C18orf1 have demonstrated enhanced TGF-β-induced cell migration, suggesting that C18orf1 normally constrains EMT processes . The mechanism appears to involve C18orf1's ability to compete with SARA for Smad2/3 binding, thereby attenuating recruitment of these Smads to the TGF-β type I receptor (ALK5) .

When studying C18orf1's role in EMT, researchers should:

• Monitor canonical EMT markers (E-cadherin, N-cadherin, vimentin) in cells with modulated C18orf1 levels

• Assess morphological changes associated with EMT

• Track cell migration and invasion capacity

• Evaluate the expression of EMT-associated transcription factors (Snail, Slug, ZEB1/2)

Understanding C18orf1's role in EMT has significant implications for cancer research, as EMT is a critical process in tumor progression and metastasis.

What is known about C18orf1 variants and their differential effects on signaling pathways?

Multiple C18orf1 isoforms have been identified, with C18orf1α subfamilies showing comparable inhibitory action on TGF-β signaling. The longest form, C18orf1α1, is typically used as a representative of the C18orf1 family in experimental settings . While all tested C18orf1α variants inhibit TGF-β signaling, their specific binding affinities and regulatory potencies may differ subtly.

Further research is needed to fully characterize the functional differences between C18orf1 variants, particularly in different tissue contexts and disease states.

How does C18orf1 function collaborate with TMEPAI in regulating TGF-β signaling in different cellular contexts?

The relationship between C18orf1 and TMEPAI represents a sophisticated regulatory system for TGF-β signaling. While both proteins inhibit TGF-β signaling through similar mechanisms (competition with SARA for Smad2/3 binding), they appear to function in distinct but complementary ways:

• C18orf1 acts as a constitutive surveillance mechanism during steady-state conditions, providing baseline regulation of TGF-β signaling .

• TMEPAI is induced upon TGF-β stimulation, creating a negative feedback loop that helps C18orf1 inhibit TGF-β signaling when cells encounter high levels of TGF-β .

This coordinated action allows for nuanced regulation under varying conditions:

• Under normal conditions, C18orf1 maintains baseline TGF-β signaling within appropriate limits

• Under high TGF-β exposure, TMEPAI expression increases to provide additional negative regulation

• The combined action prevents excessive TGF-β responses while maintaining essential signaling functions

This dual regulatory mechanism may vary across different cell types and physiological states, creating context-specific modulation of TGF-β pathway activity.

What are common difficulties in studying C18orf1 function, and how can researchers overcome them?

Studying C18orf1 presents several technical challenges:

• Low endogenous expression levels: C18orf1 may be expressed at low levels in many cell types, making detection challenging.

  • Solution: Use sensitive detection methods such as nested PCR or digital PCR for transcript analysis, and employ signal amplification techniques for protein detection.

• Functional redundancy: The overlapping function with TMEPAI can complicate interpretation of knockdown experiments.

  • Solution: Design dual knockdown/knockout experiments and rescue experiments to distinguish specific contributions of each protein.

• Context-dependent effects: C18orf1's regulatory impact may vary across cell types and conditions.

  • Solution: Test multiple cell lines and primary cultures under various stimulation conditions to establish context-specific effects.

• Antibody specificity issues: As with many understudied proteins, available antibodies may lack specificity.

  • Solution: Validate antibodies using overexpression and knockdown controls, and consider epitope-tagged constructs for reliable detection.

• Multiple isoforms: C18orf1 exists in multiple forms, which may confound functional studies.

  • Solution: Design isoform-specific detection methods and test each variant individually in functional assays.

How can researchers validate C18orf1 functional annotations in different experimental systems?

To validate C18orf1 functional annotations across experimental systems:

• Cross-validation in multiple cell lines: Test C18orf1 function in diverse cell types representing different tissues and species to confirm conservation of function.

• Complementary methodological approaches: Combine genetic (siRNA, CRISPR) and biochemical (inhibitors, mutants) approaches to corroborate findings.

• Dose-response relationships: Establish quantitative relationships between C18orf1 expression levels and functional outcomes.

• Rescue experiments: After knockdown or knockout, reintroduce wild-type or mutant versions of C18orf1 to confirm specificity of observed phenotypes.

• In vivo validation: Where possible, extend findings to animal models using tissue-specific expression or knockdown strategies.

• Patient-derived samples: Correlate findings with observations in patient-derived cells or tissues when available.

• Multi-omics integration: Combine proteomic, transcriptomic, and metabolomic approaches to build a comprehensive picture of C18orf1 function.

What is the potential role of C18orf1 in cancer biology and therapeutic development?

C18orf1's function as a negative regulator of TGF-β signaling positions it as a protein of interest in cancer research. TGF-β signaling has well-established dual roles in cancer: tumor-suppressive in early stages and pro-metastatic in advanced disease. C18orf1's ability to modulate this pathway suggests several potential implications:

• Altered expression in cancer: Changes in C18orf1 expression could contribute to dysregulated TGF-β signaling in tumors. Researchers should investigate C18orf1 expression across cancer types and stages.

• Metastasis regulation: Given that C18orf1 knockdown enhances TGF-β-induced cell migration , it may function as a metastasis suppressor. This warrants investigation in metastatic models.

• Therapeutic target potential: Modulating C18orf1 activity could represent a strategy for targeting TGF-β pathway in cancers. This could be particularly relevant in contexts where restoring appropriate TGF-β regulation is desirable.

• Biomarker development: C18orf1 expression patterns or mutations might serve as biomarkers for TGF-β pathway activity, potentially guiding therapeutic decisions.

Future research should explore correlations between C18orf1 expression/mutation status and clinical outcomes across cancer types, as well as develop experimental therapeutics that modulate C18orf1 function.

How might functional genomic screens further elucidate C18orf1's role in cellular signaling networks?

Functional genomic screens offer powerful approaches to contextualize C18orf1 within broader signaling networks:

• CRISPR-Cas9 screens: Genome-wide or focused CRISPR screens could identify synthetic lethal interactions with C18orf1 manipulation, revealing functional dependencies.

• Proteomic interaction screens: Techniques like BioID or proximity labeling could map the complete C18orf1 protein interaction network beyond the currently known Smad binding partners.

• Phosphoproteomic analysis: Examining global phosphorylation changes upon C18orf1 modulation could reveal downstream effectors beyond canonical TGF-β pathway components.

• Transcriptomic profiling: RNA-seq analysis following C18orf1 manipulation could identify all gene expression changes, potentially revealing unexpected regulatory roles.

• Validation with clinical genomics: Integrating findings with data from initiatives like The Cancer Genome Atlas could validate the clinical relevance of experimental observations, similar to approaches used for BRCA1 variant classification .

These approaches could help establish C18orf1's place within the cellular signaling ecosystem and potentially identify unexpected functions beyond TGF-β regulation.

What methodological approaches are recommended for investigating C18orf1 interactions with non-canonical TGF-β pathway components?

When investigating C18orf1 interactions with non-canonical TGF-β pathway components, researchers should employ multiple complementary approaches, beginning with unbiased screening methods followed by targeted validation experiments. It's important to consider both direct physical interactions and functional relationships that may exist without stable physical association.

How might genomic variants in C18orf1 contribute to disease phenotypes?

The investigation of genomic variants in C18orf1 requires sophisticated analysis similar to approaches used for better-characterized genes like BRCA1 . Variants of unknown significance (VUS) in C18orf1 could potentially impact TGF-β signaling regulation with downstream consequences for various disease processes.

Researchers should consider:

• Functional assays: Developing high-throughput functional screens to assess the impact of C18orf1 variants on TGF-β pathway regulation, similar to methodologies deployed for BRCA1 variant assessment .

• Clinical correlation: Analyzing C18orf1 variants in patient cohorts and correlating with disease phenotypes, particularly those involving TGF-β dysregulation.

• Structural biology approaches: Using structural analysis to predict the impact of coding variants on protein-protein interactions, especially with Smad proteins.

• In silico prediction tools: Deploying computational tools to prioritize variants for functional validation based on conservation, structural features, and predicted functional impact.

The development of a systematic classification framework for C18orf1 variants could significantly advance our understanding of its role in human disease.

What is the developmental significance of C18orf1 in embryonic and tissue-specific contexts?

Given C18orf1's role in regulating TGF-β signaling—a pathway critical for embryonic development and tissue homeostasis—investigating its developmental significance represents an important research direction. Researchers should consider:

• Temporal expression patterns: Analyzing C18orf1 expression throughout embryonic development and in adult tissues to identify stage-specific or tissue-specific roles.

• Developmental model systems: Utilizing zebrafish, Xenopus, or mouse models with C18orf1 knockdown or knockout to assess developmental consequences.

• Stem cell differentiation models: Examining C18orf1's role in directing lineage specification during differentiation of pluripotent stem cells.

• Organoid systems: Investigating how C18orf1 modulation affects the formation and maintenance of tissue-specific organoids, which could reveal context-dependent functions.